Navigation Links
Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Date:8/27/2007

SOUTH SAN FRANCISCO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at two upcoming conferences in early September:

The Thomas Weisel Partners Healthcare Conference 2007 on Wednesday, September 5, at 4:25 p.m. Eastern time at the Four Seasons Hotel in Boston.

BioCentury's "Newsmakers in the Biotech Industry" conference on Thursday, September 6, at 4:00 p.m. Eastern time at the Millennium Broadway Hotel in New York.

Dr. McMahon will provide a corporate overview, including an update on the clinical development program for picoplatin, the Company's lead product candidate.

A live audio webcast of each presentation will be available on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional information please visit http://www.poniard.com.

(C) 2007 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/18/2019)... ... ... Tune in to CNBC on Saturday, December 28th at 11:00aET to watch a ... on this program. , With a look at Avatar Partners , Advancements will ... the efficiency, safety and effectiveness of equipment, systems, and processes for the Warfighter, First ...
(Date:12/6/2019)... (PRWEB) , ... December 06, ... ... manufacturer Vascular Medcure, Inc. has received FDA 510(k) clearance for its latest ... company’s early clinical data suggests the CAPERE® offers great benefits for first-in-line ...
(Date:12/4/2019)... ... 03, 2019 , ... Absolute Antibody Ltd. , an ... the Recombinant Antibody Network (RAN), a consortium of three expert centers at the ... common goal to generate recombinant antibodies at a proteome-wide scale. Under the new ...
(Date:12/4/2019)... ... , ... A new study released today in STEM CELLS outlines how fat ... tissue) buildup – also improves the range of motion of the affected limb. The ... , The tumor-destroying capabilities of radiation therapy can be a life saver for ...
Breaking Biology Technology:
(Date:12/30/2019)... ... December 30, 2019 , ... It’s been quite a ... seen its highest sales in 2019, having hosted a multitude of team-building events and ... visited the company’s La Jolla-based venue, and the company has worked hard to accommodate ...
(Date:12/18/2019)... ... December 17, 2019 , ... PM360, a ... and diagnostics industries, has named Pharmafusion LLC as one of the most innovative ... company and its founder/CEO Jonathan Retano. Earlier in the year, Pharmafusion was featured ...
(Date:12/4/2019)... ... December 03, 2019 , ... Genedata, ... Agenus , a clinical-stage immuno-oncology company developing therapies to fight cancer, has ... platform. Agenus will use the platform to support immunotherapy and vaccine pipeline programs ...
Breaking Biology News(10 mins):